DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitro

Dimethyl sulfoxide (DMSO) is an organic solvent that is widely used as cryoprotectant for freezing cells and tissues. Clinically, DMSO is considered a potent anti-inflammatory, nerve blocker (analgesic), diuretic, vasodilator and muscle relaxer. In cells, DMSO is used to induce differentiation, as a free radical scavenger, and most notably, to prevent ice formation during cryopreservation.

Incoterms and Ancillary Materials: Navigating the Global Marketplace

With the rapid growth in personalized medicine and cell/gene therapy, quick and consistent worldwide shipment of ancillary materials is becoming more critical. Shipping variables (such as temperature maintenance in transit, packing configurations, validations, etc.) are obviously important to consider, but contract terms are often overlooked, causing misunderstandings between the buyer and seller. Incoterms® are internationally-recognized

Dr. Zylberberg is Recognized as a Leader in the Cell and Gene Therapy Industry

Every year, the Medicine Maker, a global publication with a focus on the people that drive the development of small and large molecule drugs as well as advanced therapies, compiles a list of pioneers and influencers advancing the knowledge frontier, driving clinical application, and fostering industry growth. The annual Medicine Maker Power List is compiled

The Importance of Standards and Manufacturing Needs – Recent Meetings

On Monday, March 18, the Standards Coordinating Body convened for a workshop on standards. The group discussed how standards are critical for the transfer of novel technologies from academia to clinical use. The FDA’s Judy Arcidiacono, one of the keynote speakers, discussed how standards are imperative to building the foundation of regenerative medicine innovation. The

Akron Participates in Newly Published Study Modelling Cost of Goods for Allogeneic CAR T

Cell and gene therapies have demonstrated excellent clinical results across a range of indications with chimeric antigen receptor (CAR)–T cell therapies among the first to reach market. Although these therapies are currently manufactured using patient-derived cells, therapies using healthy donor cells are in development, potentially offering avenues toward process improvement and patient access. An allogeneic

Ancillary materials: now, more than ever, at the core of new cell therapies + Exclusive discount code for Phacilitate Cell & Gene therapy summit

Raw materials have been, and will continue to be, at the core of new sets of therapies coming out over the next decade. Why? Simply because they are either scarce or limited, such as off-the-clot AB serum, or because they encompass a high risk, which is the case for animal-derived components. For this type of materials, concerns